Top

Published in:

01-01-2012

Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies

Authors: Dimitris Tousoulis, Nikolaos Papageorgiou, Alexandros Briasoulis, Emmanouel Androulakis, Marietta Charakida, Eleftherios Tsiamis, Christodoulos Stefanadis

Published in: Heart Failure Reviews | Issue 1/2012

Abstract

Chronic heart failure (CHF) is characterized by decreased nitric oxide (NO) bioavailability. In addition, the beneficial NO turns to be deleterious when it reacts with superoxide anion, leading to peroxynitrite formation. Numerous experimental and clinical studies have reported increased production of reactive oxygen species (superoxide, hydrogen peroxide, hydroxyl radical) both in animals and patients with CHF. Moreover, there are indicative data suggesting mechanisms associated with endothelial dysfunction in states of CHF, mainly attributed to decreased NO bioavailability and enhanced inactivation of the latter. Thus, such molecules appear to be potential targets in patients with CHF. These patients are strong candidates to receive a variety of therapeutic agents, some of which have known antioxidant effects. Classic treatment with statins or angiotensin converting enzyme inhibitors has been found to be beneficial in restoring NO and improving myocardial function and structure. Other agents such as sildenafil and b-blockers along with novel agents such as NO synthase transcription enhancers have been proved to be also beneficial, but their use for such a purpose is still controversial. Approaches using more-effective antioxidants or targeting myocardial oxidant-producing enzymes and oxidative or nitrosative stress might be promising strategies in the future.

Lip G, Gibbs C, Beevers D (2000) ABC of heart failure: aetiology. BMJ 320:104–107. doi:10.1136/bmj.320.7227.104 PubMedCrossRef

Jackson G, Gibbs CR, Davies MK, Lip GY (2000) ABC of heart failure. Pathophysiology. BMJ 320:167–170. doi:10.1136/bmj.320.7228.167 PubMedCrossRef

Cotton JM, Kearney MT, Shah AM (2002) Nitric oxide and myocardial function in heart failure: friend or foe? Heart 88:564–566PubMedCrossRef

Elahi MM, Naseem KM, Matata BM (2007) Nitric oxide in blood. The nitrosative-oxidative disequilibrium hypothesis on the pathogenesis of cardiovascular disease. FEBS J 274:906–923. doi:10.1111/j.1742-4658.2007.05660.x PubMedCrossRef

Pacher P, Liaudet L, Mabley J, Komjáti K, Szabó C (2002) Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol 40:1006–1016. doi:10.1016/S0735-1097(02)02062-4 PubMedCrossRef

Nediani C, Raimondi L, Borchi E, Cerbai E (2010) NO/ROS generation and nitroso/redox imbalance in heart failure: from molecular mechanisms to therapeutic implications. Antioxid Redox Signal Jul 12 [Epub ahead of print]. doi:10.1089/ars.2010.3198

Kuroda J, Sadoshima J (2010) NADPH oxidase and cardiac failure. J Cardiovasc Transl Res 3:314–320. doi:10.1007/s12265-010-9184-8 PubMedCrossRef

Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH (2005) Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 112:1763–1770. doi:10.1161/CIRCULATIONAHA.105.552174 PubMedCrossRef

Cheng G, Xu G, Cai HW, Wang HH, Bao XF (2007) Effect of atorvastatin on non-ischemic heart failure and matrix metalloproteinase-2 and 9 in rats. Acta Pharmacol Sin 28:511–517. doi:10.1111/j.1745-7254.2007.00515.x PubMedCrossRef

10.

Tousoulis D, Charakida M, Stefanadi E, Siasos G, Latsios G, Stefanadis C (2007) Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol 115:144–150. doi:10.1016/j.ijcard.2006.03.094 PubMedCrossRef

11.

Pacca SR, de Azevedo AP, De Oliveira CF, De Luca IM, De Nucci G, Antunes E (2002) Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis. J Cardiovasc Pharmacol 39:201–207PubMedCrossRef

12.

Schäfer A, Fraccarollo D, Tas P, Schmidt I, Ertl G, Bauersachs J (2004) Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism. Eur J Heart Fail 6:151–159. doi:10.1016/j.ejheart.2003.10.009 PubMedCrossRef

13.

Guzik TJ, West NE, Pillai R, Taggart DP, Channon KM (2002) Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels. Hypertension 39:1088–1094. doi:10.1161/01.HYP.0000018041.48432.B5 PubMedCrossRef

14.

Pacher P, Szabó C (2006) Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 6:136–141. doi:10.1016/j.coph.2006.01.001 PubMedCrossRef

15.

Hayashi Y, Sawa Y, Nishimura M, Fukuyama N, Ichikawa H, Ohtake S, Nakazawa H, Matsuda H (2004) Peroxynitrite, a product between nitric oxide and superoxide anion, plays a cytotoxic role in the development of post-bypass systemic inflammatory response. Eur J Cardiothorac Surg 26:276–280. doi:10.1016/j.ejcts.2004.03.033 PubMedCrossRef

16.

Pacher P, Schulz R, Liaudet L, Szabo C (2005) Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26:302–310. doi:10.1016/j.tips.2005.04.003 PubMedCrossRef

17.

Levrand S, Vannay-Bouchiche C, Pesse B, Pacher P, Feihl F, Waeber B, Liaudet L (2006) Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic Biol Med 41:886–895. doi:10.1016/j.freeradbiomed.2006.04.034 PubMedCrossRef

18.

Pacher P, Szabo C (2008) Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol 173:2–13. doi:10.2353/ajpath.2008.080019 PubMedCrossRef

19.

Bartha E, Solti I, Kereskai L et al (2009) PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovasc Res 83:501–510. doi:10.1093/cvr/cvp144 PubMedCrossRef

20.

Ungvári Z, Gupte SA, Recchia FA, Bátkai S, Pacher P (2005) Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 3:221–229PubMedCrossRef

21.

Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B, Kajstura J, Leri A, Anversa P (2001) Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 89:279–286. doi:10.1161/hh1501.094115 PubMedCrossRef

22.

Hare JM, Stamler JS (2005) NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 115:509–517. doi:10.1172/JCI200524459 PubMed

23.

Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87:315–424. doi:10.1152/physrev.00029.2006 PubMedCrossRef

24.

Tentolouris C, Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Trikas A, Toutouzas P, Stefanadis C (2004) Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. Int J Cardiol 94:301–305. doi:10.1016/j.ijcard.2003.08.002 PubMedCrossRef

25.

Tousoulis D, Homaei H, Ahmed N, Asimakopoulos G, Zouridakis E, Toutouzas P, Davies GJ (2001) Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy. Am Heart J 141:277–280. doi:10.1067/mhj.2001.112683 PubMedCrossRef

26.

Ide T, Tsutsui H, Kinugawa S, Suematsu N, Hayashidani S, Ichikawa K, Utsumi H, Machida Y, Egashira K, Takeshita A (2000) Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res 86:152–157PubMed

27.

Sam F, Kerstetter DL, Pimental DR, Mulukutla S, Tabaee A, Bristow MR, Colucci WS, Sawyer DB (2005) Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Cardiac Fail 11:473–480. doi:10.1016/j.cardfail.2005.01.007 CrossRef

28.

Tsutsui H, Ide T, Hayashidani S, Suematsu N, Utsumi H, Nakamura R, Egashira K, Takeshita A (2001) Greater susceptibility of failing cardiac myocytes to oxygen free radical-mediated injury. Cardiovasc Res 49:103–109. doi:10.1016/S0008-6363(00)00197-8 PubMedCrossRef

29.

Tsutsui H, Kinugawa S, Matsushima S (2009) Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res 81:449–456. doi:10.1093/cvr/cvn280 PubMedCrossRef

30.

Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, Takeshita A (1999) Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85:357–363PubMed

31.

Bergamini C, Cicoira M, Rossi A, Vassanelli C (2009) Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 11:444–452. doi:10.1093/eurjhf/hfp042 PubMedCrossRef

32.

Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG (2003) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111:1201–1209. doi:10.1172/JCI200314172 PubMed

33.

Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM (2003) Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41:2164–2171. doi:10.1016/S0735-1097(03)00471-6 PubMedCrossRef

34.

Akki A, Zhang M, Murdoch C, Brewer A, Shah AM (2009) NADPH oxidase signaling and cardiac myocyte function. J Mol Cell Cardiol 47:15–22. doi:10.1016/j.yjmcc.2009.04.004 PubMedCrossRef

35.

Nojiri H, Shimizu T, Funakoshi M, Yamaguchi O, Zhou H, Kawakami S, Ohta Y, Sami M, Tachibana T, Ishikawa H, Kurosawa H, Kahn RC, Otsu K, Shirasawa T (2006) Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem 281:33789–33801. doi:10.1074/jbc.M602118200 PubMedCrossRef

36.

McNally JS, Saxena A, Cai H, Dikalov S, Harrison DG (2005) Regulation of xanthine oxidoreductase protein expression by hydrogen peroxide and calcium. Arterioscl Thromb Vasc Biol 25:1623–1628. doi:10.1161/01.ATV.0000170827.16296.6e PubMedCrossRef

37.

Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, Harrison DG, Hornig B, Drexler H (2002) Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106:3073–3078. doi:10.1161/01.CIR.0000041431.57222.AF PubMedCrossRef

38.

Indik JH, Goldman S, Gaballa MA (2001) Oxidative stress contributes to vascular endothelial dysfunction in heart failure. Am J Physiol Heart Circ Physiol 281:H1767–H1770PubMed

39.

Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN (1998) Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 31:1352–1356. doi:10.1016/S0735-1097(98)00101-6 PubMedCrossRef

40.

Tousoulis D, Charakida M, Stefanadis C (2005) Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol 100:347–353. doi:10.1016/j.ijcard.2004.05.030 PubMedCrossRef

41.

Andreou I, Tousoulis D, Tentolouris C, Antoniades C, Stefanadis C (2006) Potential role of endothelial progenitor cells in the pathophysiology of heart failure: clinical implications and perspectives. Atherosclerosis 189:247–254. doi:10.1016/j.atherosclerosis.2006.06.021 PubMedCrossRef

42.

Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, Zelis R (1992) Endothelial function in chronic congestive heart failure. Am J Cardiol 69:1596–1601. doi:10.1016/0002-9149(92)90710-G PubMedCrossRef

43.

Arnold JM, Marchiori GE, Imrie JR, Burton GL, Pflugfelder PW, Kostuk WJ (1991) Large artery function in patients with chronic heart failure. Studies of brachial artery diameter and hemodynamics. Circulation 84:2418–2425PubMed

44.

Heymes C, Vanderheyden M, Bronzwaer JG, Shah AM, Paulus WJ (1999) Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 99:3009–3016PubMed

45.

Cotton JM, Kearney MT, MacCarthy PA, Grocott-Mason RM, McClean DR, Heymes C, Richardson PJ, Shah AM (2001) Effects of nitric oxide synthase inhibition on basal function and the force-frequency relationship in the normal and failing human heart in vivo. Circulation 104:2318–2323. doi:10.1161/hc4401.098515 PubMedCrossRef

46.

Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, Hintze TH (1998) Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 83:969–979PubMed

47.

Pacher P, Nivorozhkin A, Szabo C (2006) Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58:87–114. doi:10.1124/pr.58.1.6 PubMedCrossRef

48.

Grishko V, Pastukh V, Solodushko V, Gillespie M, Azuma J, Schaffer S (2003) Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage. Am J Physiol Heart Circ Physiol 285:H2364–H2372. doi:10.1152/ajpheart.00408.2003 PubMed

49.

Ishida H, Ichimori K, Hirota Y, Fukahori M, Nakazawa H (1996) Peroxynitrite-induced cardiac myocyte injury. Free Radic Biol Med 20:343–350. doi:10.1016/0891-5849(96)02060-6 PubMedCrossRef

50.

Funakoshi H, Kubota T, Kawamura N, Machida Y, Feldman AM, Tsutsui H, Shimokawa H, Takeshita A (2002) Disruption of inducible nitric oxide synthase improves beta-adrenergic inotropic responsiveness but not the survival of mice with cytokine-induced cardiomyopathy. Circ Res 90:959–965. doi:10.1161/01.RES.0000017632.83720.68 PubMedCrossRef

51.

Mihm MJ, Coyle CM, Schanbacher BL, Weinstein DM, Bauer JA (2001) Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res 49:798–807. doi:10.1016/S0008-6363(00)00307-2 PubMedCrossRef

52.

Ziolo MT, Katoh H, Bers DM (2001) Expression of inducible nitric oxide synthase depresses beta adrenergic-stimulated calcium release from the sarcoplasmic reticulum in intact ventricular myocytes. Circulation 104:2961–2966. doi:10.1161/hc4901.100379 PubMedCrossRef

53.

Mungrue IN, Gros R, You X, Pirani A, Azad A, Csont T, Schulz R, Butany J, Stewart DJ, Husain M (2002) Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, sudden death. J Clin Invest 109:735–743. doi:10.1172/JCI0213265 PubMed

54.

Heger J, Godecke A, Flogel U, Kühn-Velten WN, Schrader J (2002) Cardiac specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res 90:93–99. doi:10.1161/hh0102.102757 PubMedCrossRef

55.

Jones SP, Greer JJ, Ware PD, Yang J, Walsh K, Lefer DJ (2005) Deficiency of iNOS does not attenuate severe congestive heart failure in mice. Am J Physiol Heart Circ Physiol 288:365–370. doi:10.1152/ajpheart.00245.2004 CrossRef

56.

Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virág L, Deb A, Szabó E, Ungvári Z, Wolin MS, Groves JT, Szabó C (2003) Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107:896–904. doi:10.1161/01.CIR.0000048192.52098.DD PubMedCrossRef

57.

Szabo C, Mabley JG, Moeller SM et al (2002) Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 8:571–580PubMed

58.

Jagtap PG, Baloglu E, Southan GJ, Mabley JG, Li H, Zhou J, van Duzer J, Salzman AL, Szabó C (2005) Discovery of potent poly-(ADP-ribose) polymerase-1 inhibitors from the modification of indeno [1, 2-c]isoquinolinone. J Med Chem 48:5100–5103. doi:10.1021/jm0502891 PubMedCrossRef

59.

Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R (2000) Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 87:241–247PubMed

60.

Gao L, Wang W, Zucker IH (2008) Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. J Pharmacol Exp Ther 326:278–285. doi:10.1124/jpet.107.136028 PubMedCrossRef

61.

Castro PF, Miranda R, Verdejo HE et al (2008) Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity. J Heart Lung Transplant 27:435–441. doi:10.1016/j.healun.2008.01.012 PubMedCrossRef

62.

Erbs S, Beck EB, Linke A, Adams V, Gielen S, Kränkel N, Möbius-Winkler S, Höllriegel R, Thiele H, Hambrecht R, Schuler G (2010) High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling—results from a randomized, double-blind, and placebo-controlled study. Int J Cardiol. [Epub ahead of print]. doi:10.1016/j.ijcard.2010.02.019

63.

Andreou I, Tousoulis D, Miliou A, Tentolouris C, Zisimos K, Gounari P, Siasos G, Papageorgiou N, Papadimitriou CA, Dimopoulos MA, Stefanadis C (2010) Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis 210:194–198. doi:10.1016/j.atherosclerosis.2009.10.046 PubMedCrossRef

64.

Tousoulis D, Andreou I, Tentolouris C, Antoniades C, Papageorgiou N, Gounari P, Kotrogiannis I, Miliou A, Charakida M, Trikas A, Stefanadis C (2009) Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int J Cardiol. [Epub ahead of print]. doi:10.1016/j.ijcard.2009.05.051

65.

Tousoulis D, Antoniades C, Stefanadis C (2008) Statins ameliorate atherosclerosis induced by inhibition of nitric oxide synthase: another novel vascular protective mechanism? Int J Cardiol 123:91–93. doi:10.1016/j.ijcard.2007.04.054 PubMedCrossRef

66.

Everson WV, Smart EJ (2001) Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease. Trends Cardiovasc Med 11:246–250. doi:10.1016/S1050-1738(01)00119-0 PubMedCrossRef

67.

Sessa WC (2001) Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins? Trends Mol Med 7:189–191. doi:10.1016/S1471-4914(01)01985-2 PubMedCrossRef

68.

Laufs U, Liao JK (2000) Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 10:143–148. doi:10.1016/S1050-1738(00)00044-X PubMedCrossRef

69.

Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK (2002) Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106:57–62. doi:10.1161/01.CIR.0000020682.73694.AB PubMedCrossRef

70.

Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601–605. doi:10.1038/21224 PubMedCrossRef

71.

García-Cardeña G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, Sessa WC (1998) Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392:821–824. doi:10.1038/33934 PubMedCrossRef

72.

Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K (2003) HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 23:176–182. doi:10.1161/01.ATV.0000054659.72231.A1 PubMedCrossRef

73.

McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009) Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 120:2188–2196. doi:10.1161/CIRCULATIONAHA.109.849117 PubMedCrossRef

74.

Varin R, Mulder P, Tamion F, Richard V, Henry JP, Lallemand F, Lerebours G, Thuillez C (2000) Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress. Circulation 102:351–356PubMed

75.

Thai H, Wollmuth J, Goldman S, Gaballa M (2003) Angiotensin subtype 1 rReceptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor. J Pharmacol Exp Ther 307:1171–1178. doi:10.1124/jpet.103.054916 PubMedCrossRef

76.

Chirkov YY, Holmes AS, Martelli JD, Horowitz JD (2004) Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction. Am J Cardiol 93:1438–1440. doi:10.1016/j.amjcard.2004.02.052 PubMedCrossRef

77.

Thai HM, Do BQ, Tran TD, Gaballa MA, Goldman S (2006) Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail 12:240–245. doi:10.1016/j.cardfail.2006.01.002 PubMedCrossRef

78.

Farquharson CA, Struthers AD (2000) Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101:594–597PubMed

79.

Koifman B, Topilski I, Megidish R, Zelmanovich L, Chernihovsky T, Bykhovsy E, Keren G (2006) Effects of losartan +l-arginine on nitric oxide production, endothelial cell function, and hemodynamic variables in patients with heart failure secondary to coronary heart disease. Am J Cardiol 98:172–177. doi:10.1016/j.amjcard.2006.01.085 PubMedCrossRef

80.

Iwanaga Y, Gu Y, Dieterle T, Presotto C, Del Soldato P, Peterson KL, Ongini E, Condorelli G, Ross J Jr (2004) A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. FASEB J 18:587–588. doi:10.1096/fj.03-0872fje PubMed

81.

Liao Y, Asakura M, Takashima S, Ogai A, Asano Y, Shintani Y, Minamino T, Asanuma H, Sanada S, Kim J, Kitamura S, Tomoike H, Hori M, Kitakaze M (2004) Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 110:692–699. doi:10.1161/01.CIR.0000137831.08683.E1 PubMedCrossRef

82.

de Groot AA, Mathy MJ, van Zwieten PA, Peters SL (2007) Vasodilator effects of nebivolol in a rat model of hypertension and a rabbit model of congestive heart failure. J Cardiovasc Pharmacol 50:56–60. doi:10.1097/FJC.0b013e3180587e35 PubMedCrossRef

83.

Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ (2005) Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 127:1647–1653. doi:10.1378/chest.127.5.1647 PubMedCrossRef

84.

Horinaka S, Kobayashi N, Yagi H, Mori Y, Matsuoka H (2006) Nicorandil but not ISDN upregulates endothelial nitric oxide synthase expression, preventing left ventricular remodeling and degradation of cardiac function in Dahl salt-sensitive hypertensive rats with congestive heart failure. J Cardiovasc Pharmacol 47:629–635. doi:10.1097/01.fjc.0000211741.47960.c2 PubMedCrossRef

85.

Weiss HR, Rodriguez E, Tse J, Scholz PM (1994) Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts. Clin Exp Pharmacol Physiol 21:607–614PubMedCrossRef

86.

Sasaki N, Sato T, Ohler A, O’Rourke B, Marbán E (2000) Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 101:439–445PubMed

87.

Han J, Kim N, Joo H, Kim E, Earm YE (2002) ATP-sensitive K(+) channel activation by nitric oxide and protein kinase G in rabbit ventricular myocytes. Am J Physiol Heart Circ Physiol 283:H1545–H1554. doi:10.1152/ajpheart.01052.2001 PubMed

88.

Wohlfart P, Xu H, Endlich A, Habermeier A, Closs EI, Hübschle T, Mang C, Strobel H, Suzuki T, Kleinert H, Förstermann U, Ruetten H, Li H (2008) Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther 325:370–379. doi:10.1124/jpet.107.128009 PubMedCrossRef

89.

Sasaki K, Heeschen C, Aicher A, Ziebart T, Honold J, Urbich C, Rossig L, Koehl U, Koyanagi M, Mohamed A, Brandes RP, Martin H, Zeiher AM, Dimmeler S (2006) Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci USA 103:14537–14541. doi:10.1073/pnas.0604144103 PubMedCrossRef

90.

Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J (2008) Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 118:818–827. doi:10.1161/CIRCULATIONAHA.107.717702 PubMedCrossRef

91.

Linz W, Wohlfart P, Baader M, Breitschopf K, Falk E, Schäfer HL, Gerl M, Kramer W, Rütten H (2009) The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. Acta Pharmacol Sin 30:935–946. doi:10.1038/aps.2009.58 PubMedCrossRef

92.

Setoguchi S, Hirooka Y, Eshima K, Shimokawa H, Takeshita A (2002) Tetrahydrobiopterin improves impaired endothelium-dependent forearm vasodilation in patients with heart failure. J Cardiovasc Pharmacol 39:363–368PubMedCrossRef

93.

Gao L, Yin H, Smith S, Jr R, Chao L, Chao J (2008) Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest 88:1157–1166. doi:10.1038/labinvest.2008.85 PubMedCrossRef

94.

Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, Ogai A, Asakura M, Kim J, Minamino T, Takashima S, Sanada S, Sugimachi M, Komamura K, Mochizuki N, Kitakaze M (2009) Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 119:2568–2577. doi:10.1161/CIRCULATIONAHA.108.798561 PubMedCrossRef

95.

Chin BS, Langford NJ, Nuttall SL, Gibbs CR, Blann AD, Lip GY (2003) Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure. Eur J Heart Fail 5:171–174. doi:10.1016/S1388-9842(02)00251-9 PubMedCrossRef

96.

Nagatomo Y, Yoshikawa T, Kohno T, Yoshizawa A, Anzai T, Meguro T, Satoh T, Ogawa S (2007) Effects of beta-blocker therapy on high sensitivity C-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure. J Card Fail 13:365–371. doi:10.1016/j.cardfail.2007.02.004 PubMedCrossRef

97.

Bajcetic M, Kokic Nikolic A, Djukic M, Kosutic J, Mitrovic J, Mijalkovic D, Jovanovic I, Simeunovic S, Spasic MB, Samardzic R (2008) Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study. Clin Ther 30:702–714. doi:10.1016/j.clinthera.2008.04.007 PubMedCrossRef

98.

White M, Lepage S, Lavoie J, De Denus S, Leblanc MH, Gossard D, Whittom L, Racine N, Ducharme A, Dabouz F, Rouleau JL, Touyz R (2007) Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J Card Fail 13:86–94. doi:10.1016/j.cardfail.2006.10.013 PubMedCrossRef

99.

Ellis GR, Nightingale AK, Blackman DJ, Anderson RA, Mumford C, Timmins G, Lang D, Jackson SK, Penney MD, Lewis MJ, Frenneaux MP, Morris-Thurgood J (2002) Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress. Eur J Heart Fail 4:193–199. doi:10.1016/S1388-9842(02)00002-8 PubMedCrossRef

100.

Heeba G, Moselhy ME, Hassan M, Khalifa M, Gryglewski R, Malinski T (2009) Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1. Br J Pharmacol 156:1256–1266. doi:10.1111/j.1476-5381.2009.00125.x PubMedCrossRef

101.

Heeba G, Hassan MK, Khalifa M, Malinski T (2007) Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins. J Cardiovasc Pharmacol 50:391–398. doi:10.1097/FJC.0b013e31811f3fd0 PubMedCrossRef

102.

Daiber A, Oelze M, Coldewey M, Huth C, Schildknecht S, Bachschmid M, Nazirisadeh Y, Ullrich V, Mülsch A, Münzel T, Tsilimingas N (2005) Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun 338:1865–1874. doi:10.1016/j.bbrc.2005.10.106 PubMedCrossRef

103.

Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Haskó G, Szabó C (2002) Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 300:862–867. doi:10.1124/jpet.300.3.862 PubMedCrossRef

104.

Baljinnyam E, Hasebe N, Morihira M, Sumitomo K, Matsusaka T, Fujino T, Fukuzawa J, Ushikubi F, Kikuchi K (2006) Oral pretreatment with ebselen enhances heat shock protein 72 expression and reduces myocardial infarct size. Hypertens Res 29:905–913. doi:10.1291/hypres.29.905 PubMedCrossRef

105.

Yano M, Okuda S, Oda T, Tokuhisa T, Tateishi H, Mochizuki M, Noma T, Doi M, Kobayashi S, Yamamoto T, Ikeda Y, Ohkusa T, Ikemoto N, Matsuzaki M (2005) Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation 112:3633–3643. doi:10.1161/CIRCULATIONAHA.105.555623 PubMedCrossRef

106.

Yamada T, Nagata K, Cheng XW, Obata K, Saka M, Miyachi M, Naruse K, Nishizawa T, Noda A, Izawa H, Kuzuya M, Okumura K, Murohara T, Yokota M (2009) Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. Eur J Pharmacol 615:163–170. doi:10.1016/j.ejphar.2009.05.028 PubMedCrossRef

107.

Dover AR, Chia S, Ferguson JW, Cruden NL, Megson IL, Fox KA, Newby DE (2006) Inducible nitric oxide synthase activity does not contribute to the maintenance of peripheral vascular tone in patients with heart failure. Clin Sci (Lond) 111:275–280. doi:10.1042/CS20060104 CrossRef

108.

Schäfer A, Fraccarollo D, Widder J, Eigenthaler M, Ertl G, Bauersachs J (2009) Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer. Eur J Heart Fail 11:336–341. doi:10.1093/eurjhf/hfp005 PubMedCrossRef

109.

Castro P, Vukasovic JL, Chiong M, Díaz-Araya G, Alcaino H, Copaja M, Valenzuela R, Greig D, Pérez O, Corbalan R, Lavandero S (2005) Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. Eur J Heart Fail 7:1033–1039. doi:10.1016/j.ejheart.2004.11.009 PubMedCrossRef

110.

Nishikimi T, Karasawa T, Inaba C, Ishimura K, Tadokoro K, Koshikawa S, Yoshihara F, Nagaya N, Sakio H, Kangawa K, Matsuoka H (2009) Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure: a pilot study. Circ J 73:892–898. doi:10.1253/circj.CJ-08-0487 PubMedCrossRef

111.

Kishimoto C, Shioji K, Kinoshita M, Iwase T, Tamaki S, Fujii M, Murashige A, Maruhashi H, Takeda S, Nonogi H, Hashimoto T (2003) Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress. Int J Cardiol 91:173–178. doi:10.1016/S0167-5273(03)00002-0 PubMedCrossRef

112.

Nakamura R, Egashira K, Machida Y, Hayashidani S, Takeya M, Utsumi H, Tsutsui H, Takeshita A (2002) Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation 106:362–367. doi:10.1161/01.CIR.0000021430.04195.51 PubMedCrossRef

113.

Nishikimi T, Mori Y, Ishimura K, Ishikawa Y, Koshikawa S, Akimoto K, Minamino N, Kangawa K, Matsuoka H (2006) Chronic effect of combined treatment with omapatrilat and adrenomedullin on the progression of heart failure in rats. Am J Hypertens 19:1039–1048. doi:j.amjhyper.2006.02.013 PubMedCrossRef

114.

Cox MJ, Hawkins UA, Hoit BD, Tyagi SC (2004) Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer. Circulation 109:2123–2128. doi:10.1161/01.CIR.0000127429.53391.78 PubMedCrossRef

115.

Gounari P, Tousoulis D, Antoniades C, Kampoli AM, Stougiannos P, Papageorgiou N, Roulia G, Stefanadi E, Siasos G, Tsioufis C, Stefanadis C (2010) Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. Int J Cardiol 142:87–91. doi:10.1016/j.ijcard.2008.12.067 PubMedCrossRef

116.

Tousoulis D, Antoniades C, Vassiliadou C, Toutouza M, Pitsavos C, Tentolouris C, Trikas A, Stefanadis C (2005) Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 7:1126–1132. doi:10.1016/j.ejheart.2005.03.007 PubMedCrossRef

117.

Tousoulis D, Antoniades C, Vassiliadou C, Toutouza M, Pitsavos C, Tentolouris C, Trikas A, Stefanadis C (2005) Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91:27–31. doi:10.1136/hrt.2003.027110 PubMedCrossRef

118.

Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Pitsavos C, Vlachopoulos C, Panagiotakos D, Stefanadis C (2005) Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 178:359–363. doi:10.1136/hrt.2003.027110 PubMedCrossRef

Title: Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies
Authors: Dimitris Tousoulis
Nikolaos Papageorgiou
Alexandros Briasoulis
Emmanouel Androulakis
Marietta Charakida
Eleftherios Tsiamis
Christodoulos Stefanadis
Publication date: 01-01-2012
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 1/2012
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-011-9228-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Cardiac resynchronization therapy: the issue of non-response

The paradox of low BNP levels in obesity

Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure

Heart failure, diastolic dysfunction and atrial fibrillation; mechanistic insight of a complex inter-relationship

Chronic Chagas’ heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine

What strategies are effective for exercise adherence in heart failure? A systematic review of controlled studies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page